Igm Biosciences, Inc. Stock Price, News & Analysis

IGM Biosciences, Inc. (Nasdaq: IGMS) has announced that CEO Fred Schwarzer will present virtually at the Guggenheim 2022 Oncology Conference on February 10, 2022, at 1:00 p.m. EST. A live webcast will be available on the company's website, with a replay accessible for 90 days post-event. IGM Biosciences, based in Mountain View, California, focuses on developing engineered IgM antibodies, addressing challenges in therapeutic use since 2010. The company's proprietary IgM technology platform aims to yield advantages over traditional IgG antibodies.

IGM Biosciences, a clinical-stage biotechnology company, announced that CEO Fred Schwarzer will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 10:30 a.m. EST. The presentation will be accessible via a live webcast on the Company’s website, with a replay available for 30 days afterward. IGM Biosciences focuses on developing engineered IgM antibodies, addressing manufacturing and engineering challenges to enhance therapeutic applications compared to IgG antibodies.

IGM Biosciences, Inc. (IGMS) presented promising results from its Phase 1 trial of IGM-2323, a bispecific IgM antibody targeting CD20 x CD3, at the ASH Annual Meeting.

The trial involved 40 patients with advanced B-cell malignancies. No dose-limiting toxicities were observed, and a favorable safety profile was established. Notably, 50% of DLBCL patients and 66.67% of FL patients treated with 100 mg achieved complete responses.

Based on these results, IGM plans to initiate two Phase 2 studies to evaluate the efficacy of IGM-2323 in DLBCL and FL, which may lead to accelerated approval.

IGM Biosciences, Inc. (Nasdaq: IGMS) announced a grant agreement with the Bill & Melinda Gates Foundation to develop IgM and IgA antibodies aimed at malaria prevention. With over 200 million malaria cases and 400,000 deaths yearly, the initiative focuses on leveraging engineered antibodies for enhanced efficacy. Prior studies have shown engineered IgM antibodies could outperform IgG antibodies against infections. The partnership aims to evaluate these antibodies' effectiveness in animal models, highlighting IGM's commitment to addressing global health challenges.

IGM Biosciences, a clinical-stage biotechnology firm, will host a conference call on December 11, 2021, at 7:30 p.m. EST. This event follows the oral presentation of clinical data from its Phase 1 study of IGM-2323, a novel IgM antibody for B cell proliferative diseases, at the 63rd ASH Annual Meeting. The call will include IGM's management and Dr. Elizabeth Budde from City of Hope National Medical Center. Attendees can join by phone or via a live webcast on the company's investor website, with a replay available for 90 days.

IGM Biosciences (Nasdaq: IGMS), a clinical-stage biotechnology company, will participate in a fireside chat at the Jefferies London Healthcare Conference on November 17, 2021, at 1:40 p.m. GMT (8:40 a.m. EST). A live webcast of the event will be accessible on the Company’s website in the Investors section, with a replay available for 90 days thereafter. IGM focuses on developing engineered IgM antibodies to tackle challenges in therapeutic use, leveraging its proprietary technology platform since 2010.

IGM Biosciences, based in Mountain View, California, has announced its participation in the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 2:00 p.m. EST. The event will include a fireside chat with management, and a live webcast will be available on the Company’s website. A replay of the webcast will be accessible for 90 days after the event. IGM Biosciences specializes in developing engineered IgM antibodies and has a proprietary technology platform aimed at advancing their therapeutic applications.

IGM Biosciences (Nasdaq: IGMS) announced a financial update for Q3 2021 and plans for clinical development. The company aims to initiate Phase 2 studies for IGM-2323 targeting diffuse large B-cell and follicular lymphoma, with data expected at the 2021 ASH Annual Meeting. IGM-8444 has successfully completed Phase 1 dose escalation without significant liver toxicity. Financially, the company reported a net loss of $44.2 million in Q3 2021, with cash reserves of $265.6 million. IGM expects full-year operational expenses between $175 million and $185 million.

IGM Biosciences (Nasdaq: IGMS) has established two new business units: IGM Infectious Diseases and IGM Autoimmunity and Inflammation. This strategy aims to expand their focus beyond oncology, leveraging their novel IgM and IgA antibodies technology. Appointments include John Shiver as Chief Strategy Officer and Tong-Ming Fu as Chief Scientific Officer for the Infectious Diseases unit, while Mary Beth Harler becomes President of the Autoimmunity and Inflammation unit. This move aims to develop therapies targeting multiple disease areas.